2020

Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care

ST. LOUIS & NATICK, Mass., Oct 15, 2020 – PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate …

Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care Read More »

Pillar Biosciences welcomes new independent board member Robert Forrester

Natick, MA, Oct 1, 2020 — Pillar Biosciences, a next-generation sequencing (NGS) clinical cancer diagnostics company, today announced the addition of a new independent board member, Robert Forrester. Mr. Forrester has over two decades of experience in C-level positions in the pharmaceutical industry. Mr. Forrester joins a team of pragmatic experts in diagnostics and oncology …

Pillar Biosciences welcomes new independent board member Robert Forrester Read More »